Jan 30, 2023
Clostridium difficile infection (CDI) has emerged as a significant nosocomial infection over the years with increased incidence, recurrence and need for hospitalization. About 15% to 30% of patients who initially respond to antimicrobial therapy experience recurrent CDI (rCDI). After the first recurrence, the risk ...
Read More...
Dec 16, 2022
Clostridium difficile Infection (CDI), one of the most common nosocomial and community-acquired infections globally, is a major public health challenge. The Clostridium difficile bacteria are a toxin-producing pathogen that produces two types of toxins: toxin A (an enterotoxin) and toxin B (a cytotoxin). This toxin...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper